ZOLADEX Drug Patent Profile

Which patents cover Zoladex, and when can generic versions of Zoladex launch?

Zoladex is a drug marketed by Tersera and is included in two NDAs.

The generic ingredient in ZOLADEX is goserelin acetate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the goserelin acetate profile page.

Summary for ZOLADEX

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	45
Clinical Trials:	158
Drug Prices:	Drug price information for ZOLADEX
What excipients (inactive ingredients) are in ZOLADEX?	ZOLADEX excipients list
DailyMed Link:	ZOLADEX at DailyMed

See drug prices for ZOLADEX

Recent Clinical Trials for ZOLADEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
TerSera Therapeutics LLC	PHASE1
National Cancer Institute (NCI)	PHASE2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	PHASE2

See all ZOLADEX clinical trials

Pharmacology for ZOLADEX

Drug Class	Gonadotropin Releasing Hormone Receptor Agonist
Mechanism of Action	Gonadotropin Releasing Hormone Receptor Agonists

US Patents and Regulatory Information for ZOLADEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tersera	ZOLADEX	goserelin acetate	IMPLANT;IMPLANTATION	019726-001	Dec 29, 1989		RX	Yes	Yes
Tersera	ZOLADEX	goserelin acetate	IMPLANT;IMPLANTATION	020578-001	Jan 11, 1996		RX	Yes	Yes

Expired US Patents for ZOLADEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Tersera	ZOLADEX	goserelin acetate	IMPLANT;IMPLANTATION	020578-001	Jan 11, 1996	4,767,628
Tersera	ZOLADEX	goserelin acetate	IMPLANT;IMPLANTATION	019726-001	Dec 29, 1989	7,118,552
Tersera	ZOLADEX	goserelin acetate	IMPLANT;IMPLANTATION	019726-001	Dec 29, 1989	4,767,628
Tersera	ZOLADEX	goserelin acetate	IMPLANT;IMPLANTATION	020578-001	Jan 11, 1996	7,220,247

International Patents for ZOLADEX

See the table below for patents covering ZOLADEX around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	74434	CONTINUOUS RELEASE PHARMACEUTICAL COMPOSITIONS
South Africa	200205478	Automatically operable safety shield system for syringes.
Denmark	174120
Bulgaria	106938

Market Dynamics and Financial Trajectory for ZOLADEX

Last updated: April 17, 2026

What is ZOLADEX and How Does It Function in the Market?

ZOLADEX (goserelin acetate) is a luteinizing hormone-releasing hormone (LHRH) agonist approved primarily for prostate cancer, breast cancer, endometriosis, and early puberty indications. It is marketed by Ipsen and licensed by AstraZeneca in certain regions.

Introduced in 1989, ZOLADEX remains a key player in hormone therapy treatments, particularly for hormone-dependent cancers. Its mechanism involves downregulating hormone production to inhibit tumor growth. Its market presence relies on a mix of established patient populations, ongoing clinical trials, and regulatory approvals.

What Are the Key Market Drivers?

• Aging Global Population: The rising number of prostate and breast cancer cases enhances demand for hormone therapies such as ZOLADEX.
• Advancements in Oncology & Endocrinology: Increased adoption driven by emerging evidence supporting its efficacy and safety.
• Competitive Landscape: ZOLADEX competes with drugs like leuprorelin, goserelin (other formulations), and newer hormonal agents. Its long market presence grants brand recognition and entrenched prescribing patterns.
• Regulatory Approvals & Expansions: Approvals in emerging markets and for new indications impact sales volume.

How Do Regional Markets Influence ZOLADEX Sales?

Region	Market Size (USD billion, 2022)	Notes
North America	6.5	Leading market due to high prostate/breast cancer prevalence and insurance coverage
Europe	4.8	Mature market with extensive use in oncology and gynecology
Asia-Pacific	3.2	Rapidly growing, driven by increasing cancer burden and healthcare investments
Latin America	0.9	Emerging market with expanding access and regulatory approvals

In North America and Europe, the fixed market share persists due to established treatment protocols. Asia-Pacific shows faster growth, with CAGR around 4% projected for 2023-2030 (IQVIA, 2023).

What Are the Revenue Trends and Projections?

Historical Revenue Data (2020-2022):

Year	Global Revenue (USD million)	Growth Rate	Notes
2020	290	-	Market stabilization post-pandemic
2021	310	6.9%	Recovery, market expansion
2022	340	9.7%	Continued growth, new indications

Projected Revenue (2023-2027):

Year	Projected Revenue (USD million)	CAGR	Key Factors
2023	370	8.8%	Market expansion, patent expirations in some regions to be mitigated by new indications
2024	405	9.5%	Increasing adoption in emerging markets
2025	440	8.6%	Stabilization in mature markets, growth in China and APAC regions
2026	480	8.5%	New formulation approvals, expanding clinical indications
2027	520	8.3%	Continued growth, potential biosimilar competition in mature markets

How Do Patent Expirations and Biosimilar Competition Affect Financials?

Patent protections on ZOLADEX are set to expire in key markets by 2025. Biosimilar entrants, such as Goserelin and other GnRH analogs, threaten market share. However, brand loyalty and existing clinical data favor continued revenues in the near term.

Ipsen has announced pipeline developments, including extended-release formulations and combination therapies, to offset patent loss impacts.

What is the Investment Outlook?

Focus on pipeline innovation and geographical expansion is critical. The launch of alternative formulations in Asia and clinical trials for new indications are expected to bolster revenues. The threat posed by biosimilars could compress margins absent differentiation.

On the financial side, Ipsen reported 2022 net revenues of EUR 2.229 billion, with oncology drugs comprising around 50%. ZOLADEX's contribution remains significant though gradually decreasing due to patent cliffs.

How Does Market Competition Impact ZOLADEX?

Competitor	Market Share (2022)	Key Differentiator
Leuprorelin (AbbVie)	30%	Widely used alternative, global presence
Goserelin (Samsung, Sandoz, others)	20%	Similar efficacy, competitive pricing
Relugolix (AbbVie)	10%	Oral administration, emerging player

Biosignals indicate a trend towards oral GnRH antagonists, which could diminish ZOLADEX’s market share unless coupled with new delivery systems or indications.

Conclusion

ZOLADEX maintains a substantial footprint within hormone-dependent cancer treatments. Its future hinges on expanding into emerging markets, extending indications, and innovation in drug delivery. Competitive pressures from biosimilars and novel oral agents present headwinds over the next decade.

Key Takeaways

• The global market for ZOLADEX is driven by aging populations, increased cancer prevalence, and expanding indications.
• Revenue growth remains positive but faces pressure from patent expirations and biosimilar competition.
• Regional dynamics favor North America and Europe for current sales, with Asia-Pacific offering significant growth potential.
• Clinical pipeline developments are essential for sustainable revenue streams.
• Competitive landscape includes established GnRH analogs and emerging oral therapies.

FAQs

1. When will ZOLADEX patents expire in major markets?

   • Patents are slated for expiration in the U.S. and Europe by 2025.

2. What are the primary competitors of ZOLADEX?

   • Leuprorelin, goserelin, and relugolix.

3. How might biosimilars influence ZOLADEX sales?

   • Biosimilars could reduce market share and pressure prices if they gain regulatory approval and clinical acceptance.

4. Are there ongoing clinical trials for ZOLADEX?

   • Yes, studies focus on new indications such as combination therapies and extended-release formulations.

5. How does regional regulation impact sales?

   • Regulatory approvals in emerging markets facilitate market entry and growth, but delays or restrictions can hinder expansion.

---

References

1. IQVIA. (2023). Market analysis and projections for oncology drugs. IQVIA Institute Reports.
2. Ipsen. (2023). Annual Financial Report 2022.
3. FDA. (2020). Patent listings and expiry dates for gonadotropin-releasing hormone analogs.
4. EMA. (2022). Regulatory status updates for ZOLADEX and biosimilars.
5. Global Cancer Statistics. (2022). International Agency for Research on Cancer.